Fri, April 1, 2022

Liisa Bayko Maintained (VRTX) at Buy with Increased Target to $278 on, Apr 1st, 2022

Liisa Bayko of Evercore ISI Group, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $265 to $278 on, Apr 1st, 2022.

Liisa has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Thursday, March 31st, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Liisa


  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021